Vyant Bio, Inc.
VYNT · NASDAQ
12/31/2022 | 9/30/2022 | 6/30/2022 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.03 | 0.03 | 0.02 |
| FCF Yield | -79.59% | -15.24% | -16.79% | -9.65% |
| EV / EBITDA | 1.12 | -2.68 | -4.18 | -6.57 |
| Quality | ||||
| ROIC | -86.90% | -20.48% | -29.40% | -35.96% |
| Gross Margin | -32.61% | -69.08% | -84.24% | -27.39% |
| Cash Conversion Ratio | 0.77 | 0.65 | 0.72 | 0.43 |
| Growth | ||||
| Revenue 3-Year CAGR | -8.42% | – | – | -39.86% |
| Free Cash Flow Growth | -31.99% | 44.35% | -12.29% | -32.65% |
| Safety | ||||
| Net Debt / EBITDA | 2.38 | 2.03 | 2.30 | 3.41 |
| Interest Coverage | -54.66 | -126.93 | -394.18 | -488.56 |
| Efficiency | ||||
| Inventory Turnover | 1.15 | 3.89 | 0.70 | 0.78 |
| Cash Conversion Cycle | -256.24 | -64.24 | 85.48 | -121.89 |